Science News
from research organizations

Preventing HIV infection with anti-HIV drugs in people at risk is cost-effective

Date:
March 12, 2013
Source:
Public Library of Science
Summary:
An HIV prevention strategy in which people at risk of becoming exposed to HIV take antiretroviral drugs to reduce their chance of becoming infected (often referred to as pre-exposure prophylaxis or PrEP), may be a cost-effective method of preventing HIV in some settings, according to a new study.
Share:
       
FULL STORY

An HIV prevention strategy in which people at risk of becoming exposed to HIV take antiretroviral drugs to reduce their chance of becoming infected (often referred to as pre-exposure prophylaxis or PrEP), may be a cost-effective method of preventing HIV in some settings, according to a study by international researchers published in this week's PLOS Medicine.

In an analysis of 13 modelling studies led by Gabriela Gomez from the Department of Global Health, Academic Medical Centre, University of Amsterdam/AIGHD in The Netherlands, the authors evaluated the impact of pre-exposure prophylaxis in different populations (heterosexual couples, men who have sex with men, and people who inject drugs) in different regions and countries, such as southern Africa, Ukraine, the US, and Peru.

They found that in every setting, the cost of antiretroviral drugs was an important factor influencing the affordability of effective prevention programmes but delivery of pre-exposure prophylaxis to populations at higher risk of HIV exposure appeared to be the most cost-effective strategy. The authors also found that both behavioural changes and adherence to the pre-exposure prophylaxis drug regimens affected programme effectiveness.

The authors say: "Our findings show that pre-exposure prophylaxis has the potential to be a cost-effective addition to HIV prevention programmes in some settings."

They continue: "However, the cost-effectiveness of pre-exposure prophylaxis is likely to depend on considerations such as cost, the epidemic context, pre-exposure prophylaxis programme coverage and prioritisation strategies, as well as individual adherence levels and pre-exposure prophylaxis efficacy estimates."

The authors add: "Given that our review shows that both the setting and which population is prioritised for pre-exposure prophylaxis are critical drivers of cost-effectiveness, the next step is to conduct context-specific demonstration studies, including comprehensive cost analyses, of different prioritisation and adherence promotion strategies to ensure that the maximum benefit from the introduction of pre-exposure prophylaxis is realised within combination HIV prevention programmes."


Story Source:

The above post is reprinted from materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Gabriela B. Gomez, Annick Borquez, Kelsey K. Case, Ana Wheelock, Anna Vassall, Catherine Hankins. The Cost and Impact of Scaling Up Pre-exposure Prophylaxis for HIV Prevention: A Systematic Review of Cost-Effectiveness Modelling Studies. PLoS Medicine, 2013; 10 (3): e1001401 DOI: 10.1371/journal.pmed.1001401

Cite This Page:

Public Library of Science. "Preventing HIV infection with anti-HIV drugs in people at risk is cost-effective." ScienceDaily. ScienceDaily, 12 March 2013. <www.sciencedaily.com/releases/2013/03/130312171612.htm>.
Public Library of Science. (2013, March 12). Preventing HIV infection with anti-HIV drugs in people at risk is cost-effective. ScienceDaily. Retrieved August 31, 2015 from www.sciencedaily.com/releases/2013/03/130312171612.htm
Public Library of Science. "Preventing HIV infection with anti-HIV drugs in people at risk is cost-effective." ScienceDaily. www.sciencedaily.com/releases/2013/03/130312171612.htm (accessed August 31, 2015).

Share This Page: